- Home
- RSVR vs INBX Comparison
RSVR vs INBX Comparison
Compare RSVR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- INBX
- Stock Information
- Founded
- RSVR 2007
- INBX 2010
- Country
- RSVR United States
- INBX United States
- Employees
- RSVR N/A
- INBX N/A
- Industry
- RSVR Movies/Entertainment
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- INBX Health Care
- Exchange
- RSVR Nasdaq
- INBX Nasdaq
- Market Cap
- RSVR 504.1M
- INBX 430.2M
- IPO Year
- RSVR N/A
- INBX 2020
- Fundamental
- Price
- RSVR $7.71
- INBX $33.82
- Analyst Decision
- RSVR Strong Buy
- INBX Hold
- Analyst Count
- RSVR 1
- INBX 2
- Target Price
- RSVR $11.50
- INBX N/A
- AVG Volume (30 Days)
- RSVR 62.1K
- INBX 128.9K
- Earning Date
- RSVR 10-29-2025
- INBX 11-13-2025
- Dividend Yield
- RSVR N/A
- INBX N/A
- EPS Growth
- RSVR N/A
- INBX N/A
- EPS
- RSVR 0.12
- INBX N/A
- Revenue
- RSVR $161,553,186.00
- INBX $1,400,000.00
- Revenue This Year
- RSVR $7.17
- INBX $563.00
- Revenue Next Year
- RSVR $5.00
- INBX $230.77
- P/E Ratio
- RSVR $66.90
- INBX N/A
- Revenue Growth
- RSVR 9.65
- INBX N/A
- 52 Week Low
- RSVR $6.56
- INBX $10.81
- 52 Week High
- RSVR $9.83
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- RSVR 42.35
- INBX 73.83
- Support Level
- RSVR $7.65
- INBX $31.75
- Resistance Level
- RSVR $8.16
- INBX $37.53
- Average True Range (ATR)
- RSVR 0.19
- INBX 1.99
- MACD
- RSVR -0.03
- INBX 0.31
- Stochastic Oscillator
- RSVR 15.52
- INBX 72.30
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.